Literature DB >> 2175327

Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide.

F Y Liew1, Y Li, S Millott.   

Abstract

CBA mice develop cutaneous lesions when infected with Leishmania major. The disease development was significantly reduced by injecting into the lesion a combination of rIFN-gamma and rTNF-alpha. The doses of IFN-gamma and TNF-alpha used were suboptimal in that either cytokine alone did not have any effect. The therapeutic effect of IFN-gamma and TNF-alpha in vivo is reflected in their ability to activate macrophages to kill the intracellular parasites in vitro. The macrophage leishmanicidal activity induced by TNF-alpha and IFN-gamma can be completely inhibited by a specific inhibitor (L-NG monomethyl arginine) of nitric oxide synthesis. There was a direct correlation between the intracellular killing of the parasites and the production of nitric oxide by the macrophages. In contrast, there was no correlation between leishmanicidal activity and superoxide production by macrophages.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2175327

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  150 in total

Review 1.  Role of cytokines in the innate immune response to intracellular pathogens.

Authors:  S Stenger; M Röllinghoff
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Hong Liang; Raodoh Mohamath; Alessandro F Picone; Silvia E Z Vidal; Thomas S Vedvick; Randall F Howard; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

3.  Replication of Toxoplasma gondii, but not Trypanosoma cruzi, is regulated in human fibroblasts activated with gamma interferon: requirement of a functional JAK/STAT pathway.

Authors:  I P Cerávolo; A C Chaves; C A Bonjardim; D Sibley; A J Romanha; R T Gazzinelli
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Deficiency in tumor necrosis factor alpha activity does not impair early protective Th1 responses against blood-stage malaria.

Authors:  H Sam; Z Su; M M Stevenson
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

5.  IL-1β (-511T/C) gene polymorphism not IL-1β (+3953T/C) and LT-α (+252A/G) gene variants confers susceptibility to visceral leishmaniasis.

Authors:  Ali Moravej; Manoochehr Rasouli; Mehdi Kalani; Sadaf Asaei; Simin Kiany; Sohrab Najafipour; Amin Koohpayeh; Abbas Abdollahi
Journal:  Mol Biol Rep       Date:  2012-02-05       Impact factor: 2.316

Review 6.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

7.  The contributions of reactive oxygen intermediates and reactive nitrogen intermediates to listericidal mechanisms differ in macrophages activated pre- and postinfection.

Authors:  S Ohya; Y Tanabe; M Makino; T Nomura; H Xiong; M Arakawa; M Mitsuyama
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway.

Authors:  D Ashany; X Song; E Lacy; J Nikolic-Zugic; S M Friedman; K B Elkon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Cytokine-mediated inactivation of malarial gametocytes is dependent on the presence of white blood cells and involves reactive nitrogen intermediates.

Authors:  T S Naotunne; N D Karunaweera; K N Mendis; R Carter
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

10.  Molecular cloning, characterization, and expression in Escherichia coli of iron superoxide dismutase cDNA from Leishmania donovani chagasi.

Authors:  S O Ismail; Y A Skeiky; A Bhatia; L A Omara-Opyene; L Gedamu
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.